Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 27;127(29):6479-6486.
doi: 10.1021/acs.jpcb.3c01787. Epub 2023 Jul 10.

ALX/FPR2 Activation by Stereoisomers of D1 Resolvins Elucidating with Molecular Dynamics Simulation

Affiliations

ALX/FPR2 Activation by Stereoisomers of D1 Resolvins Elucidating with Molecular Dynamics Simulation

Vinicius S Nunes et al. J Phys Chem B. .

Abstract

Chronic inflammation contributes to several diseases, but its resolution is driven by specialized pro-resolving mediators (SPM) such as resolvin D1 (RvD1) and its epimer aspirin-triggered resolvin D1 (AT-RvD1), both biosynthesized from ω-3 fatty docosahexaenoic acid (DHA). RvD1 and AT-RvD1 have anti-inflammatory and pro-resolution potentials, and their effects could be mediated by formyl peptide receptor type 2 receptor ALX/FPR2, a G-protein-coupled receptor (GPCR). In this work, we performed 44 μs of molecular dynamics simulations with two complexes: FPR2@AT-RvD1 and FPR2@RvD1. Our results show the following: (i) in the AT-RvD1 simulations, the ALX/FPR2 receptor remained in the active state in 62% of the frames, while in the RVD1 simulations, the receptor remained in the active state in 74% of the frames; (ii) two residues, R201 and R205, of ALX/FPR2 appear, establishing interactions with both resolvins in all simulations (22 in total); (iii) RvD1 hydrogen bonds with R201 and R205 presented higher frequency than AT-RvD1; and (iv) residues R201 and R205 are the two receptor hotspots, demonstrated by the binding free calculations. Such results show that the ALX/FPR2 receptor remained in the active state for longer in the FPR2@RvD1 simulations than in the FPR2@AT-RvD1 simulations.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1:
Figure 1:
AT-RvD1 (green) and RvD1 (cyan) superposition. (A) Highlighted on carbon C17, the chiral carbon. In AT-RvD1 the carbon chain is turned to the right starting from carbon 17 (17R), while in RvD1 the carbon chain is turned to the left (17S). (B) AT-RvD1 and RvD1 molecular docking on 6OMM structure.
Figure 2:
Figure 2:
(A) NPxxY motif's location on ALX/FPR2 receptor. (B) NPxxY motif’s RMSD variation for AT-RvD1 simulations. (C) NPxxY motif’s RMSD variation for RVD1 simulations. For the calculation of RMSD we use Cα atoms.
Figure 3:
Figure 3:
(A) Distance TMH3-TMH6 variation, average I116-V247 and R123-L243 distances, analyzed in all simulations. (B) The frames' frequency where the average between the two distances was >=10.5Å. (C) and (D) Distance TMH3-TMH6 variation for AT-RvD1 simulations (C), and RvD1 simulations (D). Red line is the 10.5Å threshold.
Figure 4:
Figure 4:
Hydrogen bond frequency in FPR2@AT-RvD1 simulations (A) and FPR2@RvD1 simulations (see Tables S2 and S3). Residues that presented hydrogen bond frequency >=0.20 in at least one simulation. Hydrogen bonds between D1 resolvins and hotspots residues: (C) FPR2@AT-RvD1, S9’s pose, and (D) FPR2@RvD1, S11’s pose.
Figure 5:
Figure 5:
Average total ΔGBind and contributions (Non-Electrostatic and Electrostatic) on eleven simulations at (A) FPR2@AT-RvD1 and (B) FPR2@RvD1 (see Tables S4 and S5 ). Residue energy decomposition for FPR2@AT-RvD1 (C), and FPR2@RvD1 (D) simulations. The contribution per residue is the average in all eleven simulations (see Tables S6 and S7).

Similar articles

Cited by

References

    1. Caughey GE; James MJ; Cleland LG Prostaglandins and Leukotrienes. In Encyclopedia of Human Nutrition; Elsevier, 2005; pp 42–49.
    1. Chiang N; Barnaeva E; Hu X; Marugan J; Southall N; Ferrer M; Serhan CN Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. Cell Chem. Biol 2019, 26 (2), 244–254.e4. - PMC - PubMed
    1. Serhan CN Pro-Resolving Lipid Mediators Are Leads for Resolution Physiology. Nature 2014, 510 (7503), 92–101. - PMC - PubMed
    1. Serhan CN; Levy BD Resolvins in Inflammation: Emergence of the pro-Resolving Superfamily of Mediators Protection versus Uncontrolled Inflammation: First Responders and Resolution. J Clin Invest 2018, 128 (7), 2657–2669. - PMC - PubMed
    1. Sun Y-P; Oh SF; Uddin J; Yang R; Gotlinger K; Campbell E; Colgan SP; Petasis NA; Serhan CN Resolvin D1 and Its Aspirin-Triggered 17R Epimer. J. Biol. Chem 2007, 282 (13), 9323–9334. - PubMed

Publication types

LinkOut - more resources